A new radiopharmaceutical for bone imaging: experimental study of 99mTc-HEDTMP.
- Author:
Shu HU
1
;
Houfu DENG
;
Shubin JIANG
;
Shunzhong LUO
;
Yong LEI
Author Information
1. Department of Nuclear Medicine, Shenzhen Hospital, Peking University, Shenzhen 518036, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Bone and Bones;
diagnostic imaging;
metabolism;
Female;
Male;
Mice;
Organotechnetium Compounds;
chemical synthesis;
pharmacokinetics;
Rabbits;
Radiopharmaceuticals;
chemical synthesis;
pharmacokinetics;
Random Allocation;
Technetium Tc 99m Medronate;
pharmacokinetics;
Tissue Distribution;
Tomography, Emission-Computed, Single-Photon
- From:
Journal of Biomedical Engineering
2010;27(4):811-815
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of this study is to prepare 99mTc-HEDTMP [N-(2-hydroxyethyl) ethlenediamine-1,1,2-tri (methylene phosphonic acid), a new kind of bone seeking compound; to investigate its biological properties; and to explore the possibility of using it as a potential radiopharmaceutical for skeleton scintigraphy. HEDTMP was labeled with 99mTc by "pretinning" method, the radiochemical purity was 97.00% +/- 0.34%. 99mTc-HEDTMP was found to be stable in 5 hours in vitro with the radiochemical purity over 95% even after being diluted by physiological saline with the factor of dilution 100. The plane bone scanning of rabbits showed that 99mTc-HEDTMP was principally absorbed by skeletal system. Skull, spine and legs could be observed clearly, and were more legible than the images of 99mTc-MDP. Mice trial also indicated the high bone seeking of 99mTc-HEDTMP. The skeletal uptake was 11.92% ID/g, 13.19% ID/g, 10.14% ID/g, 10.04% ID/g, 7.71% ID/g separately at 30 minutes, 1 hour, 3 hours, 6 hours and 24 hours after the injection. Kidney seemed to be the major excretory organ. The clearance of blood was quick and the retaining amount in non-target organs was small. These results indicate that 99mTc-HEDTMP can be prepared easily, and its biological properties can be compared favorably with the commonly used bone imaging agent, and it is well worth further researching as a promising potential radiopharmaceutical in nuclide diagnosis for skeleton diseases.
